​

Verve Therapeutics Ownership | Who Owns Verve Therapeutics?

OverviewForecastRevenueFinancialsChart

Verve Therapeutics Ownership Summary

Verve Therapeutics is owned by 82.09% institutional investors, 5.10% insiders, and 12.81% retail investors. Alphabet is the largest institutional shareholder, holding 13.70% of VERV shares. ARK Genomic Revolution is the top mutual fund, with 2.92% of its assets in Verve Therapeutics shares.

VERV Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockVerve Therapeutics82.09%5.10%12.81%
SectorHealthcare Stocks 488.17%11.08%-399.26%
IndustryBiotech Stocks 306.59%11.10%-217.69%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Alphabet12.17M13.70%$136.65M
Blackrock funding, inc. /de7.36M8.29%$82.62M
Blackrock6.62M7.96%$32.31M
Pentwater capital management lp6.72M7.57%$75.47M
Vanguard group4.01M4.76%$22.60M
Casdin capital4.10M4.61%$45.99M
Schonfeld strategic advisors3.79M4.50%$21.37M
Farallon capital management3.61M4.07%$40.56M
State street3.35M4.03%$16.35M
Alpine associates management2.74M3.08%$30.75M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Arch venture management2.01M7.54%$22.56M
Alphabet12.17M6.40%$136.65M
Casdin capital4.10M4.19%$45.99M
Alpine associates management2.74M1.64%$30.75M
Chicago capital management125.38K1.03%$1.41M
Redmile group740.26K0.88%$8.31M
Adar1 capital management469.02K0.81%$5.27M
Water island capital335.59K0.54%$3.77M
Green alpha advisors50.02K0.54%$561.68K
Gabelli & co investment advisers302.40K0.52%$3.40M

Top Buyers

HolderShares% AssetsChange
Pentwater capital management lp6.72M0.49%6.72M
Alpine associates management2.74M1.64%2.74M
Farallon capital management3.61M0.17%2.70M
Hudson bay capital management lp1.75M0.07%1.75M
Schonfeld strategic advisors3.79M0.12%1.38M

Top Sellers

HolderShares% AssetsChange
Bvf inc/il---6.90M
Novo---3.00M
Ark investment management---2.94M
Woodline partners lp---2.77M
T. rowe price investment management---2.49M

New Positions

HolderShares% AssetsChangeValue
Pentwater capital management lp6.72M0.49%6.72M$75.47M
Alpine associates management2.74M1.64%2.74M$30.75M
Hudson bay capital management lp1.75M0.07%1.75M$19.63M
Nordea investment management ab675.85K0.01%675.85K$7.62M
Weiss asset management lp538.42K0.07%538.42K$6.05M

Sold Out

HolderChange
Financial gravity asset management-3.00
Nelson, van denburg & campbell wealth management group-11.00
Creekmur asset management-19.00
Riggs asset managment-22.00
Parallel advisors-23.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 2025182-6.67%72,889,758-9.79%820.95%91-7.14%676.35%
Mar 31, 202516-90.70%22,419,662-71.50%250.30%7-91.86%4-92.31%
Dec 31, 202454-69.66%26,637,343-64.58%310.40%33-65.26%13-71.11%
Sep 30, 20241766.67%75,178,380-1.22%891.06%971.04%44-4.35%
Jun 30, 2024165-76,110,149-6.75%910.95%96-4.95%4615.00%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
ARK Genomic Revolution2.47M2.92%-340.12K
Vanguard Total Stock Mkt Idx Inv2.36M2.65%-118.40K
iShares Russell 2000 ETF1.71M1.92%11.89K
Nuveen Quant Small Cap Equity R61.41M1.58%208.94K
T. Rowe Price Small-Cap Value1.17M1.32%-252.00
Vanguard Institutional Extnd Mkt Idx Tr1.07M1.20%4.24K
T. Rowe Price US Small-Cap Core Equity910.26K1.08%-41.87K
SPDR® S&P Biotech ETF918.43K1.03%-15.01K
CREF Stock R1868.91K1.03%175.51K
Vanguard Small Cap Index850.11K1.00%2.01K

Recent Insider Transactions

DateNameRoleActivityValue
Apr 02, 2025Kathiresan Sekar Chief Executive OfficerSell$40.76K
Apr 02, 2025Nickerson Joan Chief Administrative OfficerSell$11.52K
Apr 02, 2025Ashe Andrew D. See RemarksSell$11.13K
Apr 02, 2025Politi Jason Chief Technical Ops. Off.Sell$13.43K
Apr 02, 2025Dorval Allison Chief Financial OfficerSell$13.90K

Insider Transactions Trends

DateBuySell
2025 Q2-6
2025 Q1--
2024 Q4-1
2024 Q211
2024 Q1--

VERV Ownership FAQ

Who Owns Verve Therapeutics?

Verve Therapeutics shareholders are primarily institutional investors at 82.09%, followed by 5.10% insiders and 12.81% retail investors. The average institutional ownership in Verve Therapeutics's industry, Biotech Stocks , is 306.59%, which Verve Therapeutics falls below.

Who owns the most shares of Verve Therapeutics?

Verve Therapeutics’s largest shareholders are Alphabet (12.17M shares, 13.70%), Blackrock funding, inc. /de (7.36M shares, 8.29%), and Blackrock (6.62M shares, 7.96%). Together, they hold 29.95% of Verve Therapeutics’s total shares outstanding.

Does Blackrock own Verve Therapeutics?

Yes, BlackRock owns 7.96% of Verve Therapeutics, totaling 6.62M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 32.31M$. In the last quarter, BlackRock increased its holdings by 1.25M shares, a 23.20% change.

Who is Verve Therapeutics’s biggest shareholder by percentage of total assets invested?

Arch venture management is Verve Therapeutics’s biggest shareholder by percentage of total assets invested, with 7.54% of its assets in 2.01M Verve Therapeutics shares, valued at 22.56M$.

Who is the top mutual fund holder of Verve Therapeutics shares?

ARK Genomic Revolution is the top mutual fund holder of Verve Therapeutics shares, with 2.92% of its total shares outstanding invested in 2.47M Verve Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools